INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10660959		
	Filing Date		2003-09-12		
	First Named Inventor Jeffre		y George		
	Art Unit		3714		
	Examiner Name	Aashi	ish Karkhanis		
	Attorney Docket Number		60518-165		

	U.S.PATENTS					Remove		
		Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1							
If you wisl	h to a	dd additional U.S. Paten	t citatio	l n information pl	lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*			Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant s Appear			
	1	20030064805	A1	2003-04-03	Wells			
	2	20030092477	A1					
	3	20040002386	A1					
	4	20040127277	A1	2004-07-01	Walker et al.			
	5	20040209692	A1	2004-10-21	Schober et al.			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10660959		
Filing Date		2003-09-12		
First Named Inventor Jeffre		y George		
Art Unit		3714		
Examiner Name Aashi:		sh Karkhanis		
		60E40 46E		

	6	20040	1229683	A1	2084-11	1-18	Mothwurf et al					
	7	20050	070356	A1	2005-03	3-31	Mothwurf et al.					
	8	20050	1150946	A1	2005-07-14		Miodunski et al.					
If you wis	h to a	dd add	itional U.S. Publi	shed Ap	plication	n citatio	n information p	oleas	e click the Ad	d butto	n. Add	
					FORE	GN PAT	ENT DOCUM	ENT	s		Remove	
Examiner Initial*	Cite No	Forei	gn Document per ³			Kind Code ⁴	Publication Date	Name of Patentee of Applicant of cited Document			Pages,Columns,Line where Relevant Passages or Releva Figures Appear	т
	1											
If you wis	h to a	dd add	itional Foreign P	atent Do	cument	citation	information pl	ease	click the Add	butto	n Add	
				NO	I-PATE	NT LITE	RATURE DO	CUN	IENTS		Remove	
Examiner Initials*	Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city andor country where published.							Тŝ				
	1											
If you wis	h to a	dd add	itional non-pater	t literatu	re docu	ment cit	ation informat	ion p	lease click the	Add	button Add	
					EX	AMINE	R SIGNATUR	E				
Examiner	Signs	ature							Date Conside	ered		_

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EFS Web 2.0

	Application Number		10660959		
	Filing Date		2003-09-12		
INFORMATION DISCLOSURE	First Named Inventor	Jeffre	y George		
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		3714		
(Not for submission under 57 of K 1.33)	Examiner Name	Aashi	ish Karkhanis		
	Attorney Docket Numb	er	60518-165		

See Kind Code of USPTO Petert Documents at invest, ISETIG.ODV or MEPF 901.04. It better dots that issued the document, by the lockletic code (WIPO Standard S13.) If the planeses patient document, the includation of the parent for the grant or the representation precised the sensal number of the patient for sensal for some of the parent for the patient for patient

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10660959		
Filing Date		2003-09-12		
First Named Inventor Jeffre		y George		
Art Unit		3714		
Examiner Name	Aashi	ish Karkhanis		
Attorney Docket Number		60518-165		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s);

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to g any individual designated in 37 CFR 1.5(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.5(r)(c).

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

__ N--

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/James R. Yee/	Date (YYYY-MM-DD)	2007-03-23	
Name/Print	James R. Yee	Registration Number	34460	

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Operatment of Commence, P. 0. Box 1445, Alexandria, V.S. 2315-1450, D. ONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.